Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Triple Negative Breast Cancer (TNBC)
Clinical trial register · United States · industry-sponsored

Triple Negative Breast Cancer (TNBC) Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9183 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 02 Nov 2026, 03:16 UTC
9183
Studies in scope
industry-sponsored, all four open statuses
4981
Recruiting now
open to new participants
2200
Lead sponsors
across recruiting studies
Top states
Michigan 6 Texas 5 California 5 Florida 5 Tennessee 3
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Triple Negative Breast Cancer (TNBC) trials in the USA

11 of 9183 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
A Study of IOV-5001 in Adults With Advanced Solid Tumors
NCT07743723Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer
Iovance Biotherapeutics, Inc.
Phase 1/2
106
New York
2026-09
Recruiting
Immunomic Therapeutics, Inc.
Phase 1
60
Michigan, Tennessee
2026-07-14
Recruiting
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
NCT07705334Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
SHY Therapeutics
Phase 1
30
Arizona, Texas
2026-06-24
By invitation
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
Rondo Therapeutics
Phase 1
149
California, Connecticut, Michigan, New York, North Carolina, South Carolina, Tennessee, Texas
2025-11-17
Recruiting
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
NCT07190469Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer
ProteinQure Inc.
Phase 1
80
Texas, Utah
2025-09-16
Recruiting
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT07020117Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer
Aktis Oncology, Inc.
Phase 1
150
California, Florida, Iowa, Kansas, Maryland, Michigan, New York, Pennsylvania
2025-08-22
Recruiting
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT07029399HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
NiKang Therapeutics, Inc.
Phase 1
361
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2025-03-25
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
California, Florida, Michigan, Ohio, Oklahoma, Tennessee, Texas, Utah
2023-09-26
Recruiting
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
102
Michigan, Missouri, Texas, Utah
2022-12-20
Active, closed
AbbVie
Phase 1
150
Arkansas, California, Connecticut, Florida, Indiana, Missouri, North Carolina, Pennsylvania
2019-05-21
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 2 November 2026. https://priyalifescience.com/clinical-trials-usa/condition/triple-negative-breast-cancer-tnbc

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,183 studies in total at the last sync on 02 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies listing the condition Triple Negative Breast Cancer (TNBC).

How many Triple Negative Breast Cancer (TNBC) trials are recruiting in the US?

6 of the 11 studies on this page are recruiting new participants as of the 02 Nov 2026, 03:16 UTC sync. A further 2 have not yet opened recruitment, 2 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Triple Negative Breast Cancer (TNBC)), 11 studies
PhaseStudiesRecruitingShare
Phase 18572.7%
Phase 1/23127.3%

Most active sponsors

Lead sponsors with the most studies (Triple Negative Breast Cancer (TNBC))
Lead sponsorStudiesRecruiting
AbbVie10
Adcentrx Therapeutics10
Aktis Oncology, Inc.11
BreakBio Corp10
Immunomic Therapeutics, Inc.11
Iovance Biotherapeutics, Inc.10
Jacobio Pharmaceuticals Co., Ltd.11
NiKang Therapeutics, Inc.11
ProteinQure Inc.11
Rondo Therapeutics10

Top states

Top states (Triple Negative Breast Cancer (TNBC)), by number of studies with a site there
StateStudies
Michigan6
California5
Florida5
Texas5
Connecticut3
Missouri3
New York3
Tennessee3
Utah3
Iowa2
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.